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Unwilling to wait and hope for a cure, patients suffering from rare or little-studied 
diseases and their families are galvanizing research efforts and driving innovative 
approaches to develop new treatments.A decade ago, researchers knew 
that children with the rare fatal dis-
order Hutchinson-Gilford progeria 
syndrome (HGPS) appear to age a 
lifetime in just a few years, but they 
had no idea why. “There was no way 
to think about HGPS in molecular 
terms,” says Susan Michaelis of Johns 
Hopkins University School of Medi-
cine in Baltimore, Maryland. Today, 
researchers have not only identified 
the genetic defect that causes HGPS 
(a mutation in the gene encoding the 
nuclear membrane structural pro-
tein lamin A) but also are discussing 
a possible treatment using farnesyl 
transferase inhibitors (FTIs), a class 
of anticancer drug. Clinical trials of 
FTIs could begin within a year.
Michaelis, who coauthored some 
of the FTI studies, says that one 
person—Leslie Gordon—deserves 
credit for touching off this scientific 
boom. After her 22-month-old son 
was diagnosed with HGPS in 1998, 
Gordon helped to launch the Prog-
eria Research Foundation (PRF) in 
an effort to energize research into 
the disease. Since then, the organ-
ization has doled out 19 research 
grants, staged the first scientific 
workshops on HGPS, and gathered 
tissue from progeria patients and 
family members. The PRF is now 
trying to raise $2 million (about four 
times its annual budget) to bank-
roll a clinical trial to test the FTIs. 
An M.D-Ph.D. who had planned to 
specialize in pediatric ophthalmol-
ogy, Gordon says that she didn’t 
want to take on the huge task of 
creating a foundation, but the 
dearth of resources for researchers 
and for HGPS families made it nec-
essary. “We had no choice. There 
was nothing out there.”Gordon is not alone. Advocacy 
groups started by patients and their 
relatives are propelling research on 
an assortment of illnesses. They 
have taken aim at rare killers such as 
HGPS, which affects only about 40 
children worldwide, and more com-
mon diseases that they contend have 
gotten short shrift from scientists and 
pharmaceutical companies, including 
epilepsy and autism.
Patient-oriented groups date to the 
1950s, says physician and historian 
Barron Lerner of Columbia University 
in New York City. But the aggressive 
activism of the 1970s and 1980s has 
colored the attitudes of today’s par-
ticipants, who “won’t wait for science 
to get around to their disease,” he 
says. That impatience shows in tac-
tics that go beyond funneling money 
into research. Advocacy groups have 
taken over some of the scientific work 
themselves, underwriting clinical tri-
als, founding tissue banks, and in at 
least one case, opening a drug-test-
ing laboratory.
Sowing Scientific Seeds
These organizations play a crucial role 
by funding risky research that the NIH 
is reluctant to support, says Nancy 
Wexler of Columbia University in New 
York City. A veteran of science and 
activism, Wexler serves as president 
of the Hereditary Disease Foundation, 
which her father established in 1968, 
and was on the team that tracked 
down the Huntington’s disease gene 
in 1992. Advocacy groups, she notes, 
are “usually the only groups to fund 
research with pilot data.”
Such support can be doubly effec-
tive. It can enable researchers to 
amass the data necessary to gain NIH 
funding. Furthermore, a fresh source Cell 127, Novof money may entice seasoned sci-
entists and young researchers into 
working on a neglected disease. 
According to Dan Geschwind of the 
University of California, Los Angeles, 
one organization that has excelled 
at luring talented scientists is the 
Cure Autism Now (CAN) Foundation, 
launched 11 years ago by several 
families with autistic children. Former 
head of CAN’s scientific steering 
committee, Geschwind credits the 
Los Angeles-based organization with 
attracting “hundreds” of scientists 
to the field. He is one of the recruits, 
garnering CAN funds for his efforts to 
pinpoint autism susceptibility genes. 
“It’s hard to overemphasize the 
effect of CAN on raising awareness 
and bringing neuroscientists into 
research” on autism, he says.
Opening the Drug Pipeline
All advocacy groups want a cure, or 
at least a treatment without grueling 
side effects. The 1983 Orphan Drug 
Act was supposed to promote such 
breakthroughs by offering tax reduc-
tions and extended patent protection 
for companies that created drugs to 
treat rare diseases. But development 
costs are still formidable. And com-
panies that decide to take the risk can 
run into other obstacles, including a 
scarcity of patients for clinical trials. 
One of the main ways that advocacy 
groups have contributed is by work-
ing to remove some of these barriers.
For example, when it comes to new 
treatments, Kathy Giusti has deliv-
ered. The former executive at the 
pharmaceutical company G.D. Searle 
helped to start the Multiple Myeloma 
Research Foundation (MMRF) 8 years 
ago, after learning she had the incur-
able blood cancer. Although there are ember 3, 2006 ©2006 Elsevier Inc. 443
about 16,000 new cases of multiple 
myeloma in the U.S. each year, it had 
drawn little interest from pharmaceu-
tical companies, and at the time she 
was diagnosed the drug develop-
ment pipeline was empty. One conse-
quence of the more than $60 million 
the MMRF has collected for research 
is that the pipeline is flowing again, 
with three medications—Thalomid, 
Velcade, and Revlimid—recently 
approved for use against multiple 
myeloma. However, the MMRF’s 
contribution goes beyond money. 
Research on the new drugs could 
have stalled without the organiza-
tion’s ability to reach patients. To 
ensure that clinical trials for all three 
drugs would not falter because of 
insufficient volunteers, the MMRF 
alerted patients through the clinical 
trials register of its web site, enrolling 
sufficient participants to allow the tri-
als to proceed.
Progress on new epilepsy drugs 
halts long before the clinical trials 
stage, according to Warren Lam-
mert, cofounder of the Epilepsy 
Therapy Development Project. The 
“kink in the therapy pipeline” is aca-
demic scientists, says Lammert. 
“There are many, many research-
ers with interesting and exciting 
ideas who don’t know how to move 
them along to get therapeutics to 
patients.” To address this shortcom-
ing, the Epilepsy Therapy Develop-
ment Project matches academics 
who have made an encouraging dis-
covery with companies that have the 
expertise to commercialize it. Last 
year, for example, the organization 
brokered a deal to provide backing 
for Meir Bialer of Hebrew University 
of Jerusalem in Israel, who is seek-
ing gentler derivatives of the stand-
ard epilepsy treatment valproic acid. 
Although the drug quells seizures, it 
can cause liver damage and trigger 
birth defects. Bialer had identified 
some promising alternatives, says 
Lammert, but was unable to raise the 
money for further investigation. So, 
the Project and Jazz Pharmaceuti-
cals of Palo Alto, California agreed 
to split the development costs, with 
the company retaining the licensing 
rights. This matchmaking strategy 444 Cell 127, November 3, 2006 ©2006 Ehasn’t yet put any drugs into the 
clinic, Lammert says, and its suc-
cess will depend on a steady flow of 
new research findings.
A radical strategy for kick-starting 
drug research comes from James Hey-
wood of the ALS Therapy Development 
Foundation, based in Cambridge, Mas-
sachusetts. Heywood launched the 
nonprofit drug-testing laboratory after 
his brother was diagnosed with ALS 
in 1998. What deters companies from 
working on diseases like ALS is not 
the small market for medications, Hey-
wood says. It’s the lack of drug targets 
with enough scientific support to justify 
the financial risk. In effect, people are 
saying to the industry, “We want you to 
develop drugs that we don’t know will 
work.” Academic research cannot pro-
vide the supporting evidence, he says. 
“Science tends to be a craft industry. 
You have experiments that are beau-
tiful projects,” but they can’t furnish 
the quantity of information needed to 
choose whether to pursue a particular 
drug target. By taking over early drug 
testing, Heywood hopes to slash the 
cost of making this decision.
Making Connections
“One thing that the activist commu-
nity has been good at is getting sci-
entists to talk to each other,” says 
Lerner. To engineer conversation 
and cooperation, some groups have 
established formal collaborations. An 
example is Giusti’s latest effort, the 
Multiple Myeloma Research Consor-
tium (MMRC), which unites experts at 
11 of the top cancer centers in North 
America. Participants include the 
Mayo Clinic, the Dana-Farber Cancer 
Institute in Boston, and the University 
of Chicago. “It’s not that people don’t 
want to collaborate, it’s that they are 
incredibly busy,” says Giusti. Now, 
time-strapped myeloma researchers 
at these institutions have the chance 
to join projects such as a clinical trial 
of the experimental drug TKI 258, 
which blocks aberrant expression of 
the fibroblast growth factor receptor 
FGFR3 resulting from a translocation 
between chromosomes 4 and 14 in 
some multiple myeloma patients.
The Epilepsy Therapy Develop-
ment Project has launched a similar lsevier Inc.consortium. Its united front benefits 
drug companies that want to start 
clinical trials, says Lammert. Instead 
of negotiating with the institutional 
review boards at every participating 
institution, a company only needs to 
deal with one.
But informal arrangements can 
also be productive, says Wexler. 
The Hereditary Disease Foundation 
has long sponsored unconventional 
workshops on Huntington’s disease 
and related disorders. The rules ban 
slides—they discourage interaction, 
says Wexler—and require participants 
to discuss unpublished data and to 
dream up radical research strategies. 
One seemingly outrageous proposal 
from a 1979 workshop involved locat-
ing a marker for the Huntington’s dis-
ease gene, something many research-
ers at the time thought would require 
100 years, Wexler says. But after the 
participants concluded that the task 
was feasible, it took only 4 years. The 
discovery paved the way for identi-
fication of the Huntington’s disease 
gene 9 years later.
Advocacy groups serve another 
crucial function, says Wexler. They 
link scientists to patients who suffer 
from the disease, allowing research-
ers to understand why they have 
been putting in long hours. At the 
Hereditary Disease Foundation work-
shops, she always makes sure that 
researchers talk with Huntington’s 
disease patients and their families, 
so they can grasp that the illness 
“wasn’t just theoretical.” Gordon has 
followed suit in her HGPS meetings. 
For researchers who spend most of 
their time manipulating molecules in 
the lab, “that dialogue is incredibly 
motivating,” says Michaelis.
Banking on the Future
Rarity makes a disease harder to 
study. For example, even obtaining 
one blood sample from an HGPS 
patient entails a logistical feat, given 
that only 12 children with the disease 
live in the U.S. today. Another way 
that advocacy groups are promoting 
research is by setting up the cell and 
tissue collections that are invaluable 
for probing disease mechanisms and 
for preliminary drug studies.
Cancer experts are already 
requesting samples from the new 
MMRC tissue bank housed at the 
Mayo Clinic Arizona in Scottsdale, 
says director Rafael Fonseca. It 
holds bone marrow and blood from 
some 800 patients provided by the 
11 MMRC centers. Collection and 
storage of the material follows a 
standard protocol, and patients’ 
clinical data are included. Those 
features make the bank an advance 
over previous scattered attempts to 
collect myeloma patient tissue, says 
Fonseca. Gordon considers the 
HGPS tissue bank, which opened in 
2002 and contains cell lines derived 
from 54 patients, one of her most 
important contributions. It proved 
vital for recent discoveries about 
the disease because researchers 
used the material to track down the 
genetic defect underpinning HGPS 
and to conduct some of the preclini-
cal studies of FTIs.Another boon for gene hunters 
is CAN’s tissue bank, the Autism 
Genetic Resource Exchange 
(AGRE). It houses donations from 
more than 800 families, each 
with at least two autistic children. 
Geschwind and his colleagues 
relied on AGRE samples to tease 
out candidate autism genes on 
chromosome 7. Rudy Tanzi of Har-
vard Medical School heads a big-
ger search using AGRE samples 
and new Affymetrix microarrays to 
evaluate 500,000 single nucleotide 
polymorphisms (SNPs). The group 
is conducting the first “unbiased 
screen of the whole genome” for 
autism susceptibility genes, says 
Tanzi. That strategy might uncover 
genes that no one suspected were 
involved in the disorder, he says. 
The researchers have already 
begun the analysis, and Tanzi says 
he expects the data to be ready by 
the end of the year.Cell 127, NoCauses for Concern?
The new hands-on advocacy has paid 
off for many patients and researchers. 
But some scientists see drawbacks to 
this type of entrepreneurial approach. 
For example, Wexler says that the impa-
tience of some groups to find cures can 
obstruct progress instead of fostering 
it. They sometimes opt for short-term 
projects and overlook the long-term 
research necessary to understand the 
disease. Moreover, in the free-for-all 
to attract donations and the interest 
of researchers, nobody sets priorities. 
The most successful advocacy groups 
don’t necessarily represent the most 
prevalent diseases, and organiza-
tions lacking leaders with the energy 
of Gordon or the insider know-how of 
Giusti may not be as effective. Despite 
these limitations, scientists agree that 
activism by patients and their fami-
lies can keep the hunt for new treat-
ments for rare and neglected diseases 
moving forward.
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